Root Cause 2: Insulin Resistance

Insulin resistance is the metabolic lock that prevents cells from properly utilizing glucose. Under normal conditions, insulin signals cells to open GLUT4 transporters, allowing glucose to enter and fuel mitochondrial energy production. When cells become resistant to insulin, the pancreas compensates by producing more and more insulin (hyperinsulinemia), creating a cascade of metabolic dysfunction. Fasting insulin levels above 5-7 uIU/mL and a HOMA-IR score above 1.5 are early indicators of developing insulin resistance, often years before fasting glucose levels rise enough for a diabetes diagnosis.

The downstream effects of insulin resistance are devastating. Chronically elevated insulin drives visceral fat accumulation, particularly around the organs. This visceral fat is not inert storage tissue but an active endocrine organ that produces its own inflammatory cytokines, directly linking insulin resistance back to the inflammation root cause. Insulin resistance also impairs AMPK (AMP-activated protein kinase) signaling, a master metabolic sensor that regulates energy balance, autophagy, and mitochondrial biogenesis. When AMPK is suppressed, cellular cleanup processes stall, damaged mitochondria accumulate, and energy production declines.

The peptide approach to insulin resistance focuses on restoring metabolic flexibility. GLP-1 receptor agonists like semaglutide, tirzepatide, and the triple-agonist retatrutide work by enhancing insulin sensitivity, reducing appetite, and promoting fat oxidation. MOTS-c, a mitochondrial-derived peptide, acts as an exercise mimetic by activating AMPK pathways, improving glucose uptake independent of insulin signaling. AOD-9604, a fragment of human growth hormone, promotes lipolysis without the diabetogenic effects of full GH. The clinical experts who developed this framework consider metabolic restoration a prerequisite for addressing the other root causes, because cells starved of energy cannot properly execute repair programs.